Semaglutide reduces excess body fat in people with obesity
Paris enters new lockdown as Europe resumes AstraZeneca jabs
20 March 2021Obesity raises type 2 diabetes risk in women with PCOS
20 March 2021Semaglutide reduces excess body fat in people with obesity
In adults with obesity or overweight, weekly treatment with the glucagon-like peptide 1 (GLP1) receptor agonist semaglutide leads to reduced excess body fat and increased lean body mass, according to an industry-sponsored study presented virtually at ENDO 2021, the Endocrine Society’s annual meeting.
